Karyopharm Therapeutics (KPTI) AI Stock Analysis

• Market Cap: $54.89M
• Dividend Yield: N/A
• Average Volume (3M): 228.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.50
• Revenue Growth: -5.77%
• EPS Growth: -22.78%
• Country: US
• Employees: 279
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -4.32
• Shares Outstanding: 8,671,278
• 10 Day Avg. Volume: 494,784
• 30 Day Avg. Volume: 228,238
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 3.21
• Enterprise Value/Revenue: 1.28
• Enterprise Value/Gross Profit: 1.33
• Enterprise Value/Ebitda: -2.29
• 1Y Price Target: $12.80
• Price Target Upside: 110.53% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 44 Neutral
• Price Target: $6.00 ▼(-1.32% Downside)

Karyopharm Therapeutics' overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, persistent losses, and high leverage. Technical analysis indicates a bearish trend, while valuation metrics are unattractive due to a negative P/E ratio and lack of dividend yield. Despite some positive developments in clinical trials and commercial performance, significant financial challenges remain a concern.

Positive Factors

Product Revenue Growth

The growth in XPOVIO's revenue indicates strong market demand and successful commercialization, which is crucial for sustaining long-term revenue streams.

Global Expansion

Global approvals enhance market reach and diversify revenue sources, reducing dependency on any single market and supporting long-term growth potential.

Cost Optimization

Effective cost management improves operational efficiency, potentially leading to better margins and financial sustainability over the long term.

Negative Factors

Financial Constraints

Impending debt maturity poses a risk to liquidity and financial stability, potentially limiting the company's ability to invest in growth initiatives.

Declining Total Revenue

A decline in total revenue indicates challenges in maintaining growth momentum, which could impact long-term financial health if not addressed.

Net Loss

Persistent net losses highlight operational inefficiencies and financial challenges, which may hinder the company's ability to achieve profitability.

Karyopharm Therapeutics Business Overview & Revenue Model

Company Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

How the Company Makes Money

Karyopharm Therapeutics generates revenue primarily through the sale of its approved drug Xpovio, which is marketed for the treatment of multiple myeloma and certain lymphomas. The company also earns revenue from collaborations and partnerships with other pharmaceutical and biotechnology companies, which may include upfront payments, milestone payments, and royalties on future sales. Additionally, Karyopharm may receive funding from government grants or research initiatives focused on cancer therapies. The company's ability to successfully navigate clinical trials and gain further regulatory approvals for its pipeline products will be pivotal in expanding its revenue streams.

Karyopharm Therapeutics Financial Statement Overview

Summary

Karyopharm Therapeutics faces significant financial challenges, including declining revenues, persistent losses, high leverage, and negative equity. Cash flow analysis shows insufficient operational cash generation, leading to reliance on external financing.

Income Statement

Karyopharm Therapeutics has experienced declining revenue over recent years, with a negative revenue growth rate of -0.55% from 2023 to 2024. The company also faces significant profitability challenges, as indicated by negative net profit margins and EBIT margins. Despite a relatively high gross profit margin of 95.87% in 2024, the persistent net losses highlight ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows a concerning financial position with negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt relative to assets suggests significant leverage. The equity ratio is negative, further emphasizing the financial instability and potential solvency risks.

Cash Flow

Karyopharm Therapeutics has negative free cash flow, which deteriorated by 37.66% from 2023 to 2024. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. Although there was a positive financing cash flow, it is insufficient to offset the negative operating cash flow, indicating reliance on external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	137.27M	145.24M	146.03M	157.07M	209.82M	108.08M
Gross Profit	132.29M	139.23M	141.09M	151.86M	206.42M	105.38M
EBITDA	-76.92M	-38.60M	-118.42M	-139.31M	-96.98M	-167.85M
Net Income	-123.57M	-76.42M	-143.10M	-165.29M	-124.09M	-196.27M
Balance Sheet
Total Assets	104.88M	164.42M	240.44M	358.17M	305.31M	313.05M
Cash, Cash Equivalents and Short-Term Investments	38.73M	108.71M	191.44M	277.97M	228.62M	249.24M
Total Debt	94.80M	194.52M	177.02M	179.07M	180.58M	131.13M
Total Liabilities	343.81M	350.44M	376.64M	374.83M	384.98M	262.50M
Stockholders Equity	-238.93M	-186.02M	-136.21M	-16.66M	-79.67M	50.55M
Cash Flow
Free Cash Flow	-102.89M	-127.63M	-92.72M	-149.67M	-112.83M	-160.38M
Operating Cash Flow	-102.94M	-127.49M	-92.72M	-149.55M	-107.12M	-160.23M
Investing Cash Flow	55.84M	95.47M	7.94M	-104.26M	141.84M	-53.69M
Financing Cash Flow	1.04M	41.65M	1.12M	193.74M	73.65M	172.08M

Karyopharm Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.08
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPTI, the sentiment is Negative. The current price of 6.08 is above the 20-day moving average (MA) of 6.06, below the 50-day MA of 6.35, and above the 200-day MA of 6.03, indicating a bearish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 46.52 is Neutral, neither overbought nor oversold. The STOCH value of 39.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KPTI.

Karyopharm Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IPSC	―	$49.82M	―	-10.78%	―	5489.03%	86.23%
LTRN	―	$42.87M	―	-88.59%	―	―	-8.47%
KPTI	―	$54.89M	-0.43	―	―	-5.77%	-22.78%
ATNM	―	$45.55M	-1.11	-130.59%	―	-100.00%	13.14%
BTAI	―	$40.67M	-0.16	―	―	-63.88%	77.72%
MDCX	―	$47.08M	―	-340.46%	―	―	4.01%

Karyopharm Therapeutics Corporate Events

Karyopharm Therapeutics Completes Financing Transactions for Growth

On October 10, 2025, Karyopharm Therapeutics Inc. completed a series of financing transactions, including the issuance of convertible senior notes due in 2028 and 2029, and borrowed $12.5 million under its credit agreement. These transactions are aimed at strengthening the company’s financial position and supporting its strategic initiatives, potentially impacting its market standing and investor relations.

The most recent analyst rating on (KPTI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.

Karyopharm Secures $100M Financing for Clinical Trials

On October 7, 2025, Karyopharm Therapeutics announced a series of strategic financing transactions designed to provide $100 million in financial flexibility and additional capital, extending its cash runway into the second quarter of 2026. These transactions include new term loan borrowings, convertible notes, and a private placement of common stock, aimed at supporting ongoing and planned clinical trials. The company expects to generate approximately $36 million in cash proceeds from these transactions, which are set to close around October 10, 2025. This move is anticipated to strengthen Karyopharm’s balance sheet, equitize near-term debt maturities, and support its Phase 3 myelofibrosis program, potentially redefining treatment standards for the condition.

The most recent analyst rating on (KPTI) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.

Selinexor Study Withdrawal: Implications for Karyopharm Therapeutics

Study Overview: The study titled A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) aimed to evaluate the efficacy and safety of selinexor combinations in treating RR DLBCL. This study was significant as it explored new therapeutic combinations for a challenging lymphoma subtype.

Karyopharm Therapeutics Board Member Resigns Amid Career Shift

On September 5, 2025, Mansoor Raza Mirza, M.D., a member of the Board of Directors of Karyopharm Therapeutics Inc., announced his resignation effective September 8, 2025, due to competing professional demands. Dr. Mirza’s resignation is not related to any disagreements with the company, and he is also stepping down from his role as Chief Oncologist at Copenhagen University National Medical Center to pursue a new executive role in the industry. Consequently, the consulting agreement between Karyopharm and Mirza Consulting was terminated as of September 8, 2025.

The most recent analyst rating on (KPTI) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.

Karyopharm’s Earnings Call: Clinical Wins Amid Financial Strain

Karyopharm Therapeutics Faces Mixed Fortunes Amid Clinical Success and Financial Strain

Karyopharm Therapeutics Reports Q2 2025 Earnings

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on developing innovative cancer therapies, particularly through its pioneering work in nuclear export inhibition. In its latest earnings report for the second quarter of 2025, Karyopharm reported total revenue of $37.9 million, with U.S. net product revenue for its lead drug, XPOVIO, reaching $29.7 million, marking a 6% increase from the previous year. The company is on the brink of completing patient enrollment for its Phase 3 SENTRY trial in myelofibrosis, with top-line results expected in March 2026.